Loading…

Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam

Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochem...

Full description

Saved in:
Bibliographic Details
Published in:Journal of feline medicine and surgery 2012-08, Vol.14 (8), p.527-533
Main Authors: Bommer, Nicholas X, Hayes, Alison M, Scase, Timothy J, Gunn-Moore, Danièlle A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873
cites cdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873
container_end_page 533
container_issue 8
container_start_page 527
container_title Journal of feline medicine and surgery
container_volume 14
creator Bommer, Nicholas X
Hayes, Alison M
Scase, Timothy J
Gunn-Moore, Danièlle A
description Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days.
doi_str_mv 10.1177/1098612X12442041
format article
fullrecord <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11104191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1098612X12442041</sage_id><sourcerecordid>1027041656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</originalsourceid><addsrcrecordid>eNqFUU1v1DAQjRCIlsKdE_KRAwHPJLGTE0IrvqRKvYDUm-U4k66rxF7spC2_hL_LrLasAAlxsUcz7z2_5ymK5yBfA2j9BmTXKsBLwLpGWcOD4hSaCkvUjXzINY_L_fykeJLztZSyqzp8XJwg1rKFWp8WPzaTD97ZSYxklzVRfiXymm78DbcWP1MWNgxic3FZwrFCQXc7hmYfg_BBOLtkceuXrViSDdkv3Ge6o4kPm5wPcbYijmLZkliTDzZ9F_1kh4ESU_hhGg78maZ4x3bmp8Wj0U6Znt3fZ8XXD--_bD6V5xcfP2_enZeuVu1Sdq6B0UKvlHZNpWjo0FLrqOkBtWyo7hT1ne6JA-sa3diOiFANWjejkq2uzoq3B93d2s80OAocYTK75Gc2aaL15s9J8FtzFW8MAPCHd8AKL-8VUvy2Ul7M7PM-ug0U12wQUbYKser-CwXJpmtQjWKoPEBdijknGo-WQJr97s3fu2fKi9-jHAm_ls2A8gDI9orMdVwTbyn_W_An2Pq4mw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1027041656</pqid></control><display><type>article</type><title>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</title><source>SAGE Open Access</source><creator>Bommer, Nicholas X ; Hayes, Alison M ; Scase, Timothy J ; Gunn-Moore, Danièlle A</creator><creatorcontrib>Bommer, Nicholas X ; Hayes, Alison M ; Scase, Timothy J ; Gunn-Moore, Danièlle A</creatorcontrib><description>Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days.</description><identifier>ISSN: 1098-612X</identifier><identifier>ISSN: 1532-2750</identifier><identifier>EISSN: 1532-2750</identifier><identifier>DOI: 10.1177/1098612X12442041</identifier><identifier>PMID: 22408147</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animals ; bladder ; carcinoma ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - metabolism ; Carcinoma, Transitional Cell - mortality ; Carcinoma, Transitional Cell - veterinary ; Cat Diseases - drug therapy ; Cat Diseases - metabolism ; Cat Diseases - mortality ; Cats ; Cyclooxygenase 1 - drug effects ; Cyclooxygenase 1 - metabolism ; Cyclooxygenase 2 - drug effects ; Cyclooxygenase 2 - metabolism ; cystitis ; Female ; hematuria ; Immunochemistry ; immunohistochemistry ; Isoenzymes - antagonists &amp; inhibitors ; Male ; medicine ; Meloxicam ; Neoplasm Proteins - metabolism ; Original ; surgery ; Survival Analysis ; Thiazines - administration &amp; dosage ; Thiazines - pharmacology ; Thiazoles - administration &amp; dosage ; Thiazoles - pharmacology ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - metabolism ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - veterinary</subject><ispartof>Journal of feline medicine and surgery, 2012-08, Vol.14 (8), p.527-533</ispartof><rights>ISFM and AAFP 2012</rights><rights>ISFM and AAFP 2012 2012 International Society of Feline Medicine and American Association of Feline Practitioners</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</citedby><cites>FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104191/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104191/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,21947,27832,27903,27904,44924,45312,53769,53771</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1098612X12442041?utm_source=summon&amp;utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22408147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bommer, Nicholas X</creatorcontrib><creatorcontrib>Hayes, Alison M</creatorcontrib><creatorcontrib>Scase, Timothy J</creatorcontrib><creatorcontrib>Gunn-Moore, Danièlle A</creatorcontrib><title>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</title><title>Journal of feline medicine and surgery</title><addtitle>J Feline Med Surg</addtitle><description>Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days.</description><subject>Animals</subject><subject>bladder</subject><subject>carcinoma</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - metabolism</subject><subject>Carcinoma, Transitional Cell - mortality</subject><subject>Carcinoma, Transitional Cell - veterinary</subject><subject>Cat Diseases - drug therapy</subject><subject>Cat Diseases - metabolism</subject><subject>Cat Diseases - mortality</subject><subject>Cats</subject><subject>Cyclooxygenase 1 - drug effects</subject><subject>Cyclooxygenase 1 - metabolism</subject><subject>Cyclooxygenase 2 - drug effects</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>cystitis</subject><subject>Female</subject><subject>hematuria</subject><subject>Immunochemistry</subject><subject>immunohistochemistry</subject><subject>Isoenzymes - antagonists &amp; inhibitors</subject><subject>Male</subject><subject>medicine</subject><subject>Meloxicam</subject><subject>Neoplasm Proteins - metabolism</subject><subject>Original</subject><subject>surgery</subject><subject>Survival Analysis</subject><subject>Thiazines - administration &amp; dosage</subject><subject>Thiazines - pharmacology</subject><subject>Thiazoles - administration &amp; dosage</subject><subject>Thiazoles - pharmacology</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - metabolism</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - veterinary</subject><issn>1098-612X</issn><issn>1532-2750</issn><issn>1532-2750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFUU1v1DAQjRCIlsKdE_KRAwHPJLGTE0IrvqRKvYDUm-U4k66rxF7spC2_hL_LrLasAAlxsUcz7z2_5ymK5yBfA2j9BmTXKsBLwLpGWcOD4hSaCkvUjXzINY_L_fykeJLztZSyqzp8XJwg1rKFWp8WPzaTD97ZSYxklzVRfiXymm78DbcWP1MWNgxic3FZwrFCQXc7hmYfg_BBOLtkceuXrViSDdkv3Ge6o4kPm5wPcbYijmLZkliTDzZ9F_1kh4ESU_hhGg78maZ4x3bmp8Wj0U6Znt3fZ8XXD--_bD6V5xcfP2_enZeuVu1Sdq6B0UKvlHZNpWjo0FLrqOkBtWyo7hT1ne6JA-sa3diOiFANWjejkq2uzoq3B93d2s80OAocYTK75Gc2aaL15s9J8FtzFW8MAPCHd8AKL-8VUvy2Ul7M7PM-ug0U12wQUbYKser-CwXJpmtQjWKoPEBdijknGo-WQJr97s3fu2fKi9-jHAm_ls2A8gDI9orMdVwTbyn_W_An2Pq4mw</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Bommer, Nicholas X</creator><creator>Hayes, Alison M</creator><creator>Scase, Timothy J</creator><creator>Gunn-Moore, Danièlle A</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20120801</creationdate><title>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</title><author>Bommer, Nicholas X ; Hayes, Alison M ; Scase, Timothy J ; Gunn-Moore, Danièlle A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>bladder</topic><topic>carcinoma</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - metabolism</topic><topic>Carcinoma, Transitional Cell - mortality</topic><topic>Carcinoma, Transitional Cell - veterinary</topic><topic>Cat Diseases - drug therapy</topic><topic>Cat Diseases - metabolism</topic><topic>Cat Diseases - mortality</topic><topic>Cats</topic><topic>Cyclooxygenase 1 - drug effects</topic><topic>Cyclooxygenase 1 - metabolism</topic><topic>Cyclooxygenase 2 - drug effects</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>cystitis</topic><topic>Female</topic><topic>hematuria</topic><topic>Immunochemistry</topic><topic>immunohistochemistry</topic><topic>Isoenzymes - antagonists &amp; inhibitors</topic><topic>Male</topic><topic>medicine</topic><topic>Meloxicam</topic><topic>Neoplasm Proteins - metabolism</topic><topic>Original</topic><topic>surgery</topic><topic>Survival Analysis</topic><topic>Thiazines - administration &amp; dosage</topic><topic>Thiazines - pharmacology</topic><topic>Thiazoles - administration &amp; dosage</topic><topic>Thiazoles - pharmacology</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - metabolism</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - veterinary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bommer, Nicholas X</creatorcontrib><creatorcontrib>Hayes, Alison M</creatorcontrib><creatorcontrib>Scase, Timothy J</creatorcontrib><creatorcontrib>Gunn-Moore, Danièlle A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of feline medicine and surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bommer, Nicholas X</au><au>Hayes, Alison M</au><au>Scase, Timothy J</au><au>Gunn-Moore, Danièlle A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam</atitle><jtitle>Journal of feline medicine and surgery</jtitle><addtitle>J Feline Med Surg</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>14</volume><issue>8</issue><spage>527</spage><epage>533</epage><pages>527-533</pages><issn>1098-612X</issn><issn>1532-2750</issn><eissn>1532-2750</eissn><abstract>Records of 11 cats with transitional cell carcinoma of the urinary bladder, which had been treated with meloxicam, were reviewed for signalment, duration of clinical signs prior to diagnosis, results of diagnostic imaging, whether or not concurrent surgery was performed and survival. Immunohistochemical expression of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) was assessed in the tumours of seven cats. Tumour location varied greatly. The cats had a mean age of 13 years. Three cats had a previous diagnosis of feline idiopathic cystitis of up to 2008 days duration. Ten of the cats showed clinical improvement (reduction of haematuria and/or dysuria), with a mean survival time (MST) of 311 days (range 10–1064); 1-year survival of 50%. All seven bladders assessed for COX staining were COX-1 positive and five were COX-2 positive. The MST for the COX-2-positive cats was 123 days, the MST for the COX-2-negative cases was 375 days.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>22408147</pmid><doi>10.1177/1098612X12442041</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1098-612X
ispartof Journal of feline medicine and surgery, 2012-08, Vol.14 (8), p.527-533
issn 1098-612X
1532-2750
1532-2750
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11104191
source SAGE Open Access
subjects Animals
bladder
carcinoma
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - metabolism
Carcinoma, Transitional Cell - mortality
Carcinoma, Transitional Cell - veterinary
Cat Diseases - drug therapy
Cat Diseases - metabolism
Cat Diseases - mortality
Cats
Cyclooxygenase 1 - drug effects
Cyclooxygenase 1 - metabolism
Cyclooxygenase 2 - drug effects
Cyclooxygenase 2 - metabolism
cystitis
Female
hematuria
Immunochemistry
immunohistochemistry
Isoenzymes - antagonists & inhibitors
Male
medicine
Meloxicam
Neoplasm Proteins - metabolism
Original
surgery
Survival Analysis
Thiazines - administration & dosage
Thiazines - pharmacology
Thiazoles - administration & dosage
Thiazoles - pharmacology
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - metabolism
Urinary Bladder Neoplasms - mortality
Urinary Bladder Neoplasms - veterinary
title Clinical features, survival times and COX-1 and COX-2 expression in cats with transitional cell carcinoma of the urinary bladder treated with meloxicam
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20features,%20survival%20times%20and%20COX-1%20and%20COX-2%20expression%20in%20cats%20with%20transitional%20cell%20carcinoma%20of%20the%20urinary%20bladder%20treated%20with%20meloxicam&rft.jtitle=Journal%20of%20feline%20medicine%20and%20surgery&rft.au=Bommer,%20Nicholas%20X&rft.date=2012-08-01&rft.volume=14&rft.issue=8&rft.spage=527&rft.epage=533&rft.pages=527-533&rft.issn=1098-612X&rft.eissn=1532-2750&rft_id=info:doi/10.1177/1098612X12442041&rft_dat=%3Cproquest_AFRWT%3E1027041656%3C/proquest_AFRWT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-9c51fa1b667c536ed92ae8ce5b12705e496eb97be240742cf8f2213d775f60873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1027041656&rft_id=info:pmid/22408147&rft_sage_id=10.1177_1098612X12442041&rfr_iscdi=true